Rocket Pharmaceuticals downgraded by Goldman with a new price target
$RCKT
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman downgraded Rocket Pharmaceuticals from Neutral to Sell and set a new price target of $2.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2025 | $5.00 | Outperform → In-line | Evercore ISI |
| 5/28/2025 | Overweight → Neutral | Analyst | |
| 5/28/2025 | $2.00 | Neutral → Sell | Goldman |
| 5/28/2025 | $8.00 | Outperform → Market Perform | Leerink Partners |
| 5/28/2025 | $2.50 | Buy → Hold | Jefferies |
| 5/28/2025 | $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 5/27/2025 | Buy → Hold | TD Cowen | |
| 5/27/2025 | Buy → Hold | Needham |
8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)
SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)
8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)